It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the ...

CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing ...

NEFECON®, as the only in-disease IgA nephropathy (IgAN) treatment has been included in the "KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And ...

The outcome was favorable, and the glomerular filtration rate was fully restored after three months of treatment. IgA vasculitis nephritis can be severe and affect vital prognosis and renal function.

The outcome was favorable, and the glomerular filtration rate was fully restored after three months of treatment. IgA vasculitis nephritis can be severe and affect vital prognosis and renal function.

We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, ...

After the histopathological diagnosis of IgA vasculitis following the first SBE, PSL (60 mg/kg) therapy was initiated. Ganciclovir (5 mg/kg two times per day) was added to the PSL treatment according ...

Numbers of the potential cases of IgA vasculitis (IgAV) identified based on the International ... Azathioprine was the most common treatment (n=15), followed by mycophenolate mofetil (n=4), ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...